Current pharmacotherapies for alcohol used disorder (AUD) are few and relatively ineffective illustrating the need for the development of new, effective medications. Using a translational approach, our laboratory reported that ivermectin, an FDA-approved, human and animal anti-parasitic agent, can significantly reduce ethanol intake in male and female mice across different drinking paradigms. Extending this line of investigation, the current paper investigated the utility of moxidectin (MOX), an analogue of ivermectin, to reduce ethanol intake. Notably, MOX is widely held to have lower neurotoxicity potential and improved margin of safety compared to ivermectin. Using a 24-h-two-bottle choice paradigm, MOX significantly reduced ethanol intake in a dose dependent manner in both male and female C57BL/6J mice, respectively (1.25e7.5 mg/kg) and (1.25e10 mg/kg). Further, multi-day administration of MOX (2.5 mg/ kg; intraperitoneal injection) for 5 consecutive days significantly reduced ethanol intake in both the 24-h-two-bottle choice and Drinking-in-the-Dark paradigms in female mice. No overt signs of behavioral toxicity were observed. Notably in both male and female mice, MOX significantly reduced ethanol intake starting approximately 4 h post-injection. Using a Xenopus oocyte expression system, we found that MOX significantly potentiated P2X4 receptor (P2X4R) function and antagonized the inhibitory effects of ethanol on ATP-gated currents in P2X4Rs. This latter finding represents the first report of MOX having activity on P2X4Rs. In addition, MOX potentiated GABA A receptors, but to a lesser degree as compared to ivermectin supporting the hypothesis that MOX would be advantageous (compared to ivermectin) with respect to reducing contraindications. Overall, the results illustrate the potential for development of MOX as a novel pharmacotherapy for the treatment of AUD.
Introduction
Alcohol use disorder (AUD) has major health implications in the United States, affecting over 17 million people, causing more than 100,000 deaths and costing over $200 billion annually (Bouchery et al., 2011; Grant et al., 2004; Harwood and Lewin, 2000) . Despite an ongoing effort focusing on the development of new medications for AUD, there are only three-FDA approved pharmacotherapies available (disulfiram, naltrexone, and acamprosate), all which have yielded limited success Litten et al., 2012) . This is evident by the continual prevalence of high rates of uncontrolled heavy drinking and high relapse rate in patients even after long-term inpatient treatment and support (Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health, 2013). As such, the development of effective medications to treat AUD is an important public health goal (Bouchery et al., 2011; Heilig and Egli, 2006; Johnson et al., 2007; Johnson, 2010; Steensland et al., 2007) .
Our laboratory has been investigating the utility of different compounds from the avermectin family of macrocyclic lactones (eg., ivermectin, abamectin, selamectin) to be developed into novel pharmacotherapies for AUD. This class of compounds is already recognized for their ability to act on several CNS receptor targets (eg., GABA A receptors [GABA A Rs], glycine receptors, and nicotinic acetylcholine receptors) in mammals, all of which have been linked to the behavioral effects of ethanol (Dawson et al., 2000; Shan et al., 2001; Spinosa et al., 2002) . Using a combination of electrophysiology methods and rodent drinking models, we observed that the ability of these avermectins to reduce ethanol intake in mice appeared to be related to their ability to significantly reduce or eliminate the inhibitory effects of ethanol on ATP-gated P2X4 receptor (P2X4R) function in vitro . This initial in vivo-in vitro correlation implicates the use of P2X4R as a screening platform for the development of avermectins and other related analogues into novel AUD therapeutics.
Since ivermectin is already an FDA-approved drug that has been safely used in humans for several decades for the treatment of parasites (Guzzo et al., 2002; Omura, 2008) , we have been investigating the feasibility of repurposing ivermectin into a novel pharmacotherapy for AUD. In support of this hypothesis, we demonstrated that ivermectin can significantly antagonize the inhibitory effects of ethanol on P2X4R function in vitro (Asatryan et al., 2008 and significantly reduce ethanol intake in multiple drinking paradigms in both male and female mice Yardley et al., 2012 Yardley et al., , 2014 Yardley et al., , 2015 Wyatt et al., 2014) . Notably, doses of IVM as high as 10 mg/kg did not appear to cause any overt signs of organ toxicity or exert rewarding properties indicating that the psychotropic effects of IVM are dissociated from any addiction liability that can affect therapeutic compliance (Bortolato et al., 2013; Yardley et al., 2015) .
Although we have established that ivermectin is an effective agent for reducing ethanol intake in mice, recently we have begun shifting our attention to moxidectin (MOX; an ivermectin analogue) due to a number of recent reports in the literature that suggests MOX exhibits lower neurotoxicity potential compared to ivermectin (Janko and Geyer, 2013; Menez et al., 2012) . This more favorable central nervous system (CNS) safety profile is thought to be due to: 1) MOX having lower potency on GABA A Rs as compared to ivermectin which should be advantageous with respect to reducing contraindications, and 2) the differential transport across the blood brain barrier (BBB), with MOX being a weaker P-glycoprotein (P-gp) transporter substrate and less dependence on P-gp for removal from the brain (Janko and Geyer, 2013; Menez et al., 2012) . As such, the potential chronic use of MOX as a long-term AUD therapy is less likely to have complications from excessive stimulation of GABA A Rs that can lead to CNS depression and potentially coma, and also less likely to result in brain accumulation due to a deficiency in P-gp function or drug-drug interaction with other concurrent medications that may also act as P-gp substrates (Balayssac et al., 2005; Edwards, 2003; Prichard et al., 2012) . Notably, MOX is now being developed as an alternative therapy to ivermectin as an anti-parasitic agent for humans. To date, no significant clinical abnormalities have been reported (Cotreau et al., 2003; Korth-Bradley et al., 2012) . With MOX becoming approved for human use, it could represent another avermectin candidate that could be repurposed as a pharmacotherapy for AUD.
To begin to determine if MOX has the potential to be developed into a safe and effective pharmacotherapy for AUD, the present paper investigates the ability of MOX to reduce ethanol intake in male and female mice using a 24-h-two-bottle choice paradigm. The lower limit of alcohol consumed in this model suggests that it mimics social drinking (Blednov et al., 2010) . We also utilized a Drinking-in-the-Dark (DID) paradigm where the amount of alcohol consumed is much higher in a short period of time (compared to the 24 h model) and results in blood ethanol concentrations (BECs) similar to human binge-like drinking (i.e., > 80 mg%) (Lowery et al., 2010; Neasta et al., 2010; Rhodes et al., 2005) . Both of these models are well-validated and routinely used to assess changes in ethanol intake in rodents.
To begin to investigate the mechanism of MOX's anti-alcohol effects, we used a two-electrode voltage clamp, Xenopus oocyte expression system (Davies et al., 2002 (Davies et al., , 2005 to test the ability of MOX to potentiate P2X4R function and to antagonize the inhibitory effects of ethanol on P2X4Rs as previously demonstrated for ivermectin and abamectin . We also compared the potentiating effects of MOX versus ivermectin on GABA A Rs. Overall, the findings support the development of MOX as a pharmacotherapy for the treatment of AUD.
Materials

Drugs
MOX (10 mg/kg) solution (Boehringer Ingelheim, St. Joseph, MO) was diluted in a 0.9% sodium chloride solution (saline) to a concentration that would allow for an injection volume of 0.01 mL/g of body weight. We used saline as the diluent based on previous pilot work where we found that propylene glycol ([1,2 propanediol], [Alfa Aesar, Ward Hill, MA]), the solvent used by the manufacturer to dissolve MOX (when diluted in saline to equivalent concentrations as in the MOX [10 mg/kg] solution) showed comparable drinking level as saline injection alone, and both the solvent and saline did not cause significant reduction in ethanol intake. 190 proof USP ethanol (Koptec, King of Prussia, PA) was diluted in water to achieve a 10% (10E) v/v solution or a 20% (20E) v/v solution (20E).
Animals
Studies were performed on drug-naïve male and female C57BL/ 6J mice purchased from Jackson Laboratory (Bar Harbor, ME). All studies were conducted with mice 10e12 weeks of age. Mice were first acclimated to the housing facility for one week and grouphoused (4 mice per cage) in polycarbonate/polysulfone cages at a 12 h light/dark cycle (lights off at 12:00PM) with ad libitum access to food and water in rooms maintained at 22 C. All procedures in this study were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and all efforts were made to minimize animal suffering. The USC Institutional Animal Care and Use Committee approved the protocols.
Methods
24-h-two-bottle choice paradigm
All experiments numbering noted in the methods section corresponds to the figures numbering in the results section for the ease of reading (i.e., Experiment 1a corresponds to Fig. 1a ).
For our initial investigations, we used a 24-h-two-bottle choice paradigm that is widely used to assess changes in drinking behaviors (Belknap et al., 1993; Yoneyama et al., 2008; Yardley et al., 2012) with modifications as presented previously (Yardley et al., 2012) . Mice were individually housed 3 days before the start of the study and had 24 h access to two inverted water bottles (graduated cylinders) with metal sippers placed on the cage tops. Food was distributed near both bottles to avoid food associated tube preferences.
Experiment 1a: A within-subjects design was used with one group of female mice (n ¼ 12) that were allowed free access to two bottles, one containing 10E and the other water. 10E position was alternated every other day during testing period to avoid for side preference. Body weights and food intake (weight of food on day 1 subtract weight of food on day 2 ¼ food consumed for the 24 h period) were monitored daily during testing period. Fluid intake was recorded (fluid level on inverted cylinder on day 2 subtract fluid level on day 1 ¼ fluid consumed for the 24 h period) daily during testing period. Daily observations on normal overt behaviors of mice were also noted (normal: constant active movement, responsive to experimenter intervention, and fur groomed; abnormal: lack of movement, hunched postured and hurdling in corner, unresponsive to experimenter intervention, and piloerection of fur). Daily 10E intake was measured until it stabilized (±10% variability from the mean of the last 3 days). Next mice were habituated to saline injections (intraperitoneal; i. p.) until 10E intake again stabilized. Mice then received one dose of MOX (5 mg/ kg). Animals were injected with saline on the day following MOX injection. Change in drinking over the 24 h following each injection (saline or MOX) was measured. Pre-MOX is the day prior to MOX injection, and post-MOX is the day following MOX injection.
Experiment 1b: followed similar procedures as described in experiment 1a. A new group of female mice (n ¼ 16) were allowed free access to 10E and water. After saline habituation and obtaining stable baseline 10E intake, all mice received one injection (i. p.) of MOX (0.65, 1.25, 2.5, 5, 7.5, or 10 mg/kg). Animals were injected with saline on subsequent days after MOX injection until 10E drinking returned to baseline levels (which took about 1e2 days), and then mice were injected with another dose of MOX. This pattern of MOX administration continued until all doses of a particular study were completed. The doses were given in random fashion with no particular order.
Experiment 1c: followed similar procedures as described in experiment 1b, except male mice (n ¼ 12) were used in this study and the doses of MOX tested were 1.25, 2.5, 5, and 7.5 mg/kg. Experiment 2: We conducted an hour by hour evaluation using the two-bottle choice paradigm and a between-subjects design. A new group of female mice was habituated to saline injection. After establishing baseline drinking level, mice were split into two groups based on average 10E intake and subsequently received either one injection (i. p.) of MOX (2.5 mg/kg) or saline (controls) (n ¼ 18 MOX versus 10 saline controls). Following drug injection, 10E intake was monitored for the two groups every hour up to the 9th h.
Experiment 3: We also conducted a multi-day MOX study using the two-bottle choice paradigm and a between-subjects design. All the female mice from experiment 2 received saline injection during the washout period until 10E intake returned to baseline, then received either daily injection (i. p.) of MOX (2.5 mg/kg) or saline (controls) for 5 consecutive days in the multi-day MOX study (n ¼ 18 MOX versus 10 saline controls). 10E intake was monitored for 24 h period after each injection for 5 consecutive days.
Drinking-in-the-dark (DID) paradigm
Experiment 4: The DID model is widely used to assess changes in binge-like drinking behaviors. A modified version of this procedure (Lowery et al., 2010; Neasta et al., 2010; Rhodes et al., 2005) was utilized during which mice had daily limited access (2 h) to one bottle containing 20E beginning at the third hour into the circadian dark phase, which results in mice reaching high BECs in a short period of time. A new group of female mice was used and following habituation to saline injection and establishing baseline drinking level, mice were split into two groups based on average 20E intake and subsequently received either one injection (i. p.) of MOX (2.5 mg/kg) or saline daily for 5 days (n ¼ 18 MOX versus 10 saline controls). MOX or saline was administered 4 h prior to the start of the drinking session based on our time-course study for MOX which indicates that it took 4 h post-injection before significant reduction in ethanol intake was observed (Fig. 2) . 20E intake was monitored during the 2 h drinking session for 5 consecutive days. A single bottle of water was continuously available between ethanol access periods.
Complementary RNA (cRNA) and complementary DNA (cDNA) injections in Xenopus laevis oocyte
Stage V or VI Xenopus oocytes (purchased from EcoCyte Bioscience, Austin, TX) were injected with 20 ng cRNA of rat p2rx4 Fig. 1 . Acute administration of MOX significantly reduced 10E intake in female and male C57BL/6J mice, in a dose-dependent manner, using a 24-h-two-bottle choice paradigm. MOX was administered after habituation with saline injection and attaining stable drinking levels. Bars represent levels from the day prior to MOX injection (white; pre-MOX), the day of MOX injection (black; MOX), and the day after MOX injection (gray; post-MOX). a) MOX (5 mg/kg) significantly reduce 10E intake in female mice. Values represent mean ± SEM for 12 mice, *p < 0.05, #p < 0.0001 versus pre-MOX, Tukey multiple comparison post-hoc test. b) MOX (1.25, 2.5, 5, 7.5, and 10 mg/ kg) significantly reduced 10E intake in female mice. Values represent mean ± SEM for 16 mice per dose group, *p < 0.05, #p < 0.0001 versus respective pre-MOX condition, Bonferroni's post-hoc test. c) MOX (1.25, 2.5, 5, and 7.5 mg/kg) significantly reduced 10E intake in male mice. Values represent mean ± SEM for 12 mice per dose group, **p < 0.01, #p < 0.0001 versus respective pre-MOX condition, Bonferroni's post-hoc test.
gene or 1 ng cDNA for GABA A R (a1:b2:g2:, 1:1:10) as described previously using the Nanoject II Nanoliter injection system (Drummond Scientific, Broomall, PA). Injected oocytes were stored at 16 C in incubation medium containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 5 mM HEPES, and 2.5 mM pyruvic acid with 1% heat inactivated HyClone ® horse serum (VWR, San Dimas, CA) and 0.05 mg/mL gentamycin, adjusted to pH 7.5. Electrophysiological experiments were conducted 24e48 h after cRNA injections.
Whole cell two-electrode voltage clamp recordings
Two electrode voltage clamp recordings were performed using the OC-725C oocyte clamp (Warner Instruments, Hamden, CT) as previously described elsewhere (Davies et al., 2002 (Davies et al., , 2005 . The oocytes were voltage clamped at À70 mV and the currents were recorded on a strip-chart recorder (Barnstead Instrument, Dubuqe, IA).
Experiment 5: P2X4R oocytes were continuously perfused at a rate of 3e4 mL/min at room temperature with modified Ringers buffer containing (in mM) 110 NaCl, 2.5 KCl, 10 HEPES and 1.8 BaCl 2 , pH 7.5, using a peristaltic pump (Rainin Instrument, Oakland, CA). To induce currents, submaximal concentrations (EC 10 ) of adenosine 5'-triphosphate (ATP, Sigma, St. Louis, MO) were used, which produced 10% of maximal effect induced by 100 mM ATP. We have shown previously that the use of EC 10 can maximize the effects of ethanol and minimize receptor desensitization Davies et al., 2002 Davies et al., , 2005 . Ethanol and/or drugs were applied after stable response to ATP EC 10 was obtained. A washout period of 5 min was allowed between each application to allow for re-sensitization of the receptor Davies et al., 2002 Davies et al., , 2005 Popova et al., 2010) . Effects of ethanol (25 or 50 mM) or MOX ([0.5 and 1 mM], powder dissolved in DMSO to 10 mM stock solution, then dissolved to appropriate concentration in perfusion buffer) were tested alone and in combination during co-application with ATP. Pilot studies determined that the effects of ethanol and MOX on P2X4R were concentration-dependent and reversible (n ¼ 4e6 oocytes).
Experiment 6: Effects of MOX (0.1, 0.5, and 1 mM) or ivermectin (0.1, 0.5, and 1 mM) on GABA A Rs were tested using GABA EC 10 . Oocytes were perfused at a rate of 3e4 mL/ min at room temperature with modified Bart's saline containing (in mM) 83 NaCl, 1 KCl, 10 HEPES, 0.82 MgSO 4 , 2.4 NaHCO 3 , 0.91 CaCl 2 , and 0.33 Ca(NO 3 ) 2 , pH 7.5. Drugs were applied after stable response to GABA EC 10 was obtained. A washout period of 5 min was allowed between each GABA application. Due to irreversible and nonwashable effects on GABA-induced currents, each oocyte was tested for one concentration of MOX or ivermectin (n ¼ 4e12 oocytes per data point).
Statistical analyses
Ethanol intake for all studies was calculated as g/kg [g of pure ethanol per kg of body weight; 10E intake ¼ (volume of 10E consumed in mL Â 0.07893 g/mL)/body weight in kg; 20E intake ¼ (volume of 20E consumed in mL Â 0.15786 g/mL)/body weight in kg]. The dependent variables include ethanol intake (g/ kg), water (mL), food intake (g), and change in mouse weight (g). Experiment 1a: one-way ANOVA was used to assess the treatment effect of MOX with time [saline pre-treatment (pre-MOX), MOX dose, saline post-treatment (post-MOX)] as a repeated measures factor on the dependent variable. Experiment 1bc: two-way ANOVA was used to assess the treatment effect of MOX with each MOX dose (0.65e10 mg/kg) or time [saline pre-treatment (pre-MOX), MOX dose, saline post-treatment (post-MOX)] as a repeated measures factor on the dependent variable. Experiment 2: two-way ANOVA was used to assess the treatment effect of MOX between groups (MOX versus saline-injected) or with time (for each hour post-injection) as a repeated-measures factor on the dependent variables. Experiment 3e4: two-way ANOVA was used to assess the treatment effect of 5-day MOX administration between groups (MOX versus saline-injected) or with time (for each day of MOX administration) as a repeated-measures factor on the dependent variables. Experiment 5e6: two-tailed, unpaired, individual Student's t-test was used to assess for difference between treatment groups.
Significant main effects and interactions of the ANOVAs were further investigated with post-hoc tests (i.e., Tukey's for one way ANOVA and Bonferroni for two-way ANOVA). For all studies significance was set at p 0.05.
All graphs and statistical analyses were generated using Prism (GraphPad Software Inc., San Diego, CA).
Results
Acute administration of MOX (5 mg/kg) decreased 10E intake in female mice
Using female C57BL/6J mice, we tested the effects of acute administration of MOX (5 mg/kg) on ethanol intake using a 24-h- two-bottle choice paradigm (10E versus water). This dose was previously shown to be the lowest ivermectin dose that produced maximal reduction in ethanol consumption (Yardley et al., 2012) . Baseline 10E intake was first obtained followed by habituation to saline injections.
As illustrated in Fig. 1a , 10E intake stabilized at 14.14 g/kg following saline injections (pre-MOX). Acute administration of MOX (5 mg/kg) significantly reduced ethanol intake in excess of 44% when analyzed across time (pre-MOX, MOX, post-MOX) [F(2, 33) ¼ 8.045, p ¼ 0.0014], and 10E intake remained significantly lower than pre-MOX on the day following MOX treatment (by more than 20%, shown as post-MOX, p < 0.05) (Fig. 1a) .
MOX decreased 10E intake in a dose-dependent manner in female mice
We extended our initial single dose MOX study to one where several doses of MOX were tested in random fashion (saline, 5, 10, 2.5, 7.5, and 0.65 mg/kg) in order to begin to establish the dose characteristics of MOX in relation to 10E intake. Two-way ANOVA revealed a significant effect of MOX administration on ethanol intake when analyzed across time (pre-MOX, MOX, post-MOX) [F(2, 312) ¼ 84.60, p < 0.001]. The analysis of the MOX doses (0.65e10 mg) indicated that MOX significantly reduced ethanol intake in a dose-dependent manner in female mice (Fig. 1b) [F(5, 312) ¼ 4.299, p < 0.001]. The interaction between time and dose was significant [F(10, 312), 5.057, p < 0.001]. Bonferroni post-hoc comparisons between pre-MOX and MOX data indicated that 2.5 mg/kg MOX was the lowest dose that caused a maximum significant reduction in ethanol intake [~44% reduction, (t ¼ 5.467, p < 0.001)]. For the MOX doses that significantly reduced 10E intake, we found that 10E intake returned to comparable pre-MOX ethanol intake levels within 1e2 days post-MOX injection (data not shown). The lowest dose of MOX tested (0.65 mg/kg) did not significantly reduce 10E intake compared to pre-MOX level. In addition, following saline habituation, further injections with saline alone did not significantly affect 10E intake (Fig. 1b, . MOX (all doses tested, pre-MOX compared to MOX) did not cause significant changes in body weight (data not shown) or showed any signs of abnormal overt behaviors such as lack of movement with hunched postured and hurdling in corner, unresponsive to experimenter intervention, and piloerection of fur.
MOX decreased 10E intake in a dose-dependent manner in male mice
Extending our line of investigation, we also tested the utility of MOX using male C57BL/6 mice. Two-way ANOVA revealed a significant effect of MOX administration on ethanol intake when analyzed across time (pre-MOX, MOX, post-MOX) [F(1, 11) ¼ 68.43, p < 0.0001]. The analysis of the MOX doses (1.25e7.5 mg/kg) indicated that MOX significantly reduced ethanol intake in a dosedependent manner in male mice (Fig. 1b) . MOX (all doses tested, pre-MOX compared to MOX) did not cause significant changes in body weight or showed any signs of abnormal overt behaviors.
Time course of the effect of MOX on ethanol intake in female mice
To gain insight to the pharmacokinetics of MOX distribution and its impact on ethanol intake, we evaluated the time course of the effect of MOX on hourly ethanol intake using a 24-h-two-bottle choice paradigm. Using this paradigm, we previously reported that the onset of significant activity for ivermectin was approximately 9 h post-administration (Fig. 2 inset) (Yardley et al., 2012) . After stable 10E intake was obtained, either MOX (2.5 mg/kg, previously determined as the minimum effective dose) or saline was administered to female mice 1 h before the first reading. (Fig. 2) . The interaction between time and MOX dose was not significant. We conducted planned comparison which showed that ethanol intake was significantly decreased starting at 4 h after MOX administration (Fig. 2) .
Multiple day dosing of MOX administration reduced ethanol intake in female mice using a 24-h-two-bottle choice paradigm
Alcoholism is a chronic disorder. As such, an effective pharmacotherapy for AUD will mostly need to be taken chronically. To begin to investigate the utility of MOX for chronic use, we tested the effects of MOX (2.5 mg/kg) administered for 5 consecutive days in female mice using a 24-h-two-bottle choice paradigm. On the day prior to drug/vehicle treatment, there was no significant difference in average 10E intake for the MOX (12.26 g/kg) or control (12.68 g/ kg) groups. We tested the effect of MOX versus saline, administered daily, on 10E intake over a 5-day period (Fig. 3a) . When analyzed across the 5-day treatment period, we found that MOX significantly reduced ethanol intake compared to the saline-injected control group [F(1,24) ¼ 26.35, p < 0.001]. There was also a significant effect on 10E intake when analyzed across time (day) [F(4, 96) ¼ 8.730, p < 0.001]. The interaction between treatment and time was not significant.
MOX treatment did not significantly change either water or food intake between the two groups when analyzed across 5-day treatment period and time (day) (Fig. 3bec) . There was a significant effect of MOX treatment [F(1, 24) ¼ 24.4, p < 0.0001] and time (day) [F(4, 96) ¼ 5.951, p < 0.001] on change in body weight with no significant interaction between treatment and time (Fig. 3d) .
Multiple day dosing of MOX administration reduced ethanol intake in female mice using a drinking-in-the-dark paradigm
We extended our multiple dosing of MOX administration using a modified version of the DID paradigm in female mice (Lowery et al., 2010; Neasta et al., 2010; Rhodes et al., 2005) . One day prior to treatment, there was no significant difference in average 20E intake for the MOX (2.91 g/kg) and control (3.02 g/kg) groups. We tested the effect of MOX (2.5 mg/kg) versus saline, administered daily, 4 h prior to the start of the drinking sessions on 20E intake over a 5-day period (Fig. 4a) . MOX administration consistently reduced 20E intake across the testing period, and the reduction was significant when analyzed across time (day) [F(3,27) ¼ 8.862, p < 0.001] but not across the 5-day treatment period. There was no interaction between treatment and time.
MOX treatment did not cause any significant changes in food intake between the two groups (Fig. 4b) when analyzed across the 5-day treatment period and time (day). We did observe a significant effect of MOX treatment on body weight [F(1, 24) ¼ 12.01, p < 0.001)] but no significant effect of time (day) on change in body weight (Fig. 4c) , and there was no interaction between treatment and time.
MOX positively modulated ATP-gated P2X4Rs and antagonized the inhibitory effects of ethanol on P2X4R function
We investigated the effects of 0.5 mM and 1 mM MOX alone, and in combination with behaviorally relevant concentrations of ethanol (25 and 50 mM) on ATP-induced currents in P2X4Rs in vitro. In agreement with previous studies Davies et al., 2005; Popova et al., 2010) , ethanol (25 and 50 mM) significantly inhibited ATP-gated P2X4R currents (Fig. 5aeb) . In the presence of ATP, MOX (0.5 and 1 mM) produced a comparable degree of potentiation of P2X4R activity (Fig. 5aeb) .
When tested in the presence of ethanol, 0.5 mM MOX significantly reduced the inhibitory effect caused by 25 mM (p ¼ 0.003) but not 50 mM ethanol on ATP-gated P2X4R activated currents (Fig. 5a ). In contrast, 1 mM MOX eliminated the inhibitory effect of ethanol at both concentrations, 25 mM (p ¼ 0.0028) and 50 mM (p ¼ 0.029) (Fig. 4b) .
MOX positively modulated GABA A R activity
We also tested the effects of MOX on GABA A Rs since we, and others have previously reported that ivermectin and other related avermectins have significant GABAergic activity Janko and Geyer, 2013; Menez et al., 2012) . We used a1b2g2 GABA A Rs due to their predominant expression in the CNS in mammals (Sigel and Steinmann, 2012) . As illustrated in Fig. 6 , we found that MOX and ivermectin each significantly increased GABA A R function. There was no significant difference between the extent of potentiation of GABA A R function between MOX and ivermectin at 0.1 mM. However, the degree of MOX potentiation was significantly less (compared to ivermectin) when tested at higher concentrations [0.5 mM (p ¼ 0.0072) and 1 mM (p ¼ 0.00092)].
Discussion
The present study was the first investigation to test the utility of MOX as a pharmacotherapy for AUD. Several key findings came from this work. Testing the hypothesis that administration of MOX can reduce ethanol intake in male and female mice, we found that acute and repeated administration of MOX significantly reduced ethanol intake using two well-established drinking paradigms. Fig. 3 . Daily administration of MOX (2.5 mg/kg £ 5 days) significantly reduced 10E intake in female C57BL/6J mice using a 24-h-two-bottle choice paradigm. Following habituation with saline injection and attaining stable drinking levels, MOX was administered for 5 consecutive days. Squares represent MOX and circles represent saline. a) MOX (2.5 mg/kg) significantly reduced 10E intake across the 5 treatment days. The effects of water intake, food intake, and weight are presented in panels, b, c, and d, respectively. Values represent mean ± SEM cumulative intake for MOX (18 mice) and saline (10 mice), **p < 0.01, ***p < 0.001, #p < 0.0001 versus saline-treated group, Bonferroni's post-hoc test.
Using a Xenopus oocyte expression system, we found that MOX significantly reduced the inhibitory effects of ethanol on P2X4Rs suggesting that at least a portion of MOX's anti-ethanol effects may be linked to activity on P2X4Rs. Using a 5-day MOX administration treatment regimen with a 24-h-two-bottle choice paradigm, we found that the reduction in ethanol intake was significant and remained consistent over the 5-day period (with an average reduction of approximately 40% compared to saline-injected controls). Importantly, no significant decrease in food consumption or weight loss, or other abnormalities in overt behavior (e.g., lack of movement and constant hurdling in corner, unresponsive to experimenter intervention, and piloerection of fur) were noted. These findings are well aligned with our previous work demonstrating that chronic administration of ivermectin was efficacious in reducing ethanol intake and well tolerated (Yardley et al., 2012 (Yardley et al., , 2015 . Finally, MOX also consistently reduced ethanol intake when tested using a 5-day DID paradigm (average reduction approximately 30%).
Several reports have suggested that different rodent drinking models involve overlapping and distinct neurobiological mechanisms (Crabbe et al., 2011; McBride and Li, 1998) . MOX has been purported to act several different neurotransmitter targets that can regulate ethanol behavior through multiple mechanisms Wolstenholme and Rogers, 2005; Yamaguchi et al., 2012) . Thus, it is possible that a higher dose of MOX may exert a different degree of activity on a single or combination of these targets leading to more pronounced reduction in ethanol intake using the DID paradigm. Collectively, these results support the development of MOX as a novel pharmacotherapy for the treatment of AUD and illustrate the potential for P2X4Rs as a novel target for AUD drug development.
The fact that the administration of MOX as illustrated in our multi-day studies did not result in any consistent, significant effect on water or food intake suggests the drug is well tolerated. As shown, we did find that MOX did cause some reduction in weight and the change remained stable over the 5-day period. We do not know the reason for this change, but it could be due to a loss of caloric intake linked to the decreased ethanol consumption that was caused by MOX. Notably, all animals appeared healthy and remained alive at the end of the study, suggesting that MOX does not have any unexpected interactions with ethanol that could lead Fig. 6 . MOX (0.1, 0.5, and 1 mM) has a weaker modulatory activity in GABA A Rs than ivermectin. At low 0.1 mM concentration, MOX potentiated GABA A Rs to similar extent as ivermectin. At 0.5 mM and above, the effect of MOX was significantly smaller compared to that of ivermectin. Values represent mean ± SEM for 4 to 12 oocytes per data point, **p < 0.01, ***p < 0.001 versus respective control, two-tailed unpaired Student's t-test. Fig. 7 . Structures of (a) ivermectin and (b) MOX. Major structural differences are noted. C13: ivermectin contains a disaccharide while MOX is protonated; C23: MOX has a methoxime; C25: ivermectin is a mixture of C25-ethyl (~10%) or C25-methyl (~90%) groups while MOX has a dimethyl-butyl substituent.
to lethality or negative changes in behavior.
In the current investigation, we found that the reduction in ethanol intake reached significance approximately 4 h after MOX administration. This represents a significant improvement in onset of effect as compared to the 9 h window necessary for initial onset of ivermectin activity (Yardley et al., 2012) . This finding suggests that MOX can reach effective therapeutic (anti-alcohol effect) brain concentrations more rapidly versus ivermectin and is consistent with previous findings suggesting that MOX has improved BBB penetration compared to ivermectin KikiMvouaka et al., 2010) .
The faster onset to the initial reduction of ethanol intake may be explained by the differences in structural features and physiochemical properties of ivermectin and MOX. Ivermectin and MOX share a common macrocyclic lactone ring and are distinguishable by specific substituents at the C13, C23, and C25 position (Fig. 7) . These substituents play a role in influencing the lipophilicity and affinity for P-gp transporters. The higher lipophilicity of MOX compared to ivermectin (log P MOX ¼ 6, P ivermectin ¼ 4.8) is consistent with its higher entrance into the brain, greater accumulation in adipose tissue, and longer retention time in the organism (Baoliang et al., 2006; Lanusse et al., 1997; Prichard et al., 2012) . In addition, MOX has been shown to have a weaker affinity for P-gp compared to ivermectin and other avermectins based on structural and biochemical studies. The disaccharide sugar moiety found on ivermectin is absent on MOX. This moiety is thought to govern the affinity for P-gp (Lespine et al., 2007) .
Interestingly, despite reaching higher brain levels, MOX is predicted to have a better neurotoxicity profile when compared to ivermectin, which is thought to be due to 1) the differential transport across the blood brain barrier (BBB), with MOX being less dependent on P-gp for removal from the brain and less likely to accumulate due to a deficiency in P-gp function or drug-drug interaction arising from concurrent medications that may also act as P-gp substrates (Kiki-Mvouaka et al., 2010; Menez et al., 2012) , and 2) the differential interaction with GABA A Rs, with MOX exhibiting lower activity at these receptors (Janko and Geyer, 2013; Menez et al., 2012) . In agreement with the latter, our results also indicated that the degree of MOX potentiation of GABA A Rs was significantly less as compared to ivermectin. At higher concentrations, we found that ivermectin continued to increase the degree of GABA A Rs activity whereas the effects of MOX quickly reached a plateau. This result, coupled with the aforementioned benefits of MOX (weak P-gp target; better BBB penetration), suggests that chronic use of MOX as a long-term treatment for AUD should be more favorable as compared to ivermectin because there should be less complications arising from potential brain accumulation and/ or over-stimulation of GABA A Rs that can lead to CNS depression and potentially coma. Balayssac et al., 2005) .
Importantly, MOX is currently undergoing clinical development as an alternative to ivermectin for treating the parasite Onchocerca volvulus, and to date, no significant clinical abnormalities or serious adverse events have been reported over for these investigations (Cotreau et al., 2003; Korth-Bradley et al., 2012) . The faster onset time, robust efficacy and favorable safety profile continue to support the development of MOX as a novel pharmacotherapy for the treatment of AUD.
In addition to our in vivo results, as reported above, we found that MOX positively modulated ATP-gated currents in P2X4Rs and antagonized the inhibitory effects of ethanol on P2X4R function. This is the first evidence demonstrating that a compound from the milbemycin subfamily of macrocyclic lactones can act on P2X4Rs in vitro. This finding is in good agreement with our earlier investigations where we demonstrated that both ivermectin and abamectin significantly antagonized the inhibitory effects of ethanol on P2X4R function .
In addition to activity on P2X4Rs, we (in this study) and others report that MOX can also act on other brain targets including GABA A Rs, glycine, and nAChRs Wolstenholme and Rogers, 2005; Yamaguchi et al., 2012) . Notably, all of these receptors have been linked to the modulation of mesolimbic dopamine activity and regulation of ethanol behavior (Davies, 2003; Xiao et al., 2009) . Thus, it is likely that the reduction of ethanol intake, by MOX, as presented in the current investigation reflects a cumulative effect of MOX activity on several different classes of receptors including P2X4Rs. Additional studies are necessary before definite conclusions can be drawn.
In that this was the first investigation focusing on MOX, several limitations should be noted. First, the majority of the results presented here were conducted using female mice and we did not monitor for the effects of estrous cycle, which could potentially confound the interpretation of the results. However, in our doseresponse study we used both male and female mice (Fig. 1bec) . As presented, there was a significant reduction of ethanol intake by MOX in both male and female mice and the degree of reduction was similar for both groups. In addition, we also utilized a saline-treated control group in both of the 5-day investigations using female mice (24-h-bottle-bottle-choice and DID studies), it is unlikely that the differences in 10E and 20E intake between the MOX and saline group could be attributed to the estrous cycle. This conclusion is similar to previous work where no systematic changes in ethanol intake across weeks of baseline consumption in female C57BL/6 mice were observed . Collectively, these results suggests that the estrous cycle is unlikely to have an impact on the anti-alcohol effects of MOX and further supports the utility of MOX as a pharmacotherapy for AUD in both male and female. In future investigations, we plan to continue evaluating the effects of MOX administration on ethanol intake in both male and female mice using long-term drinking paradigms.
Second, we did not test other tastants such as sucrose or quinine in this study. Previously, we reported that ivermectin produced a significant reduction in 24 h saccharin consumption, but did not significantly alter operant sucrose self-administration (Yardley et al., 2012) . Based on this finding, it would not be unreasonable to predict that MOX may also act on other tastants, but this should not reduce the utility of MOX for its anti-alcohol effects. Third, in the DID investigation, we did not measure BECs. As such, we cannot definitively conclude that the BEC levels achieved in our DID study reached binge-like drinking levels. However, the levels of ethanol intake achieved in our study were similar to levels of ethanol intake reported by others where BECs were recorded (Wilcox et al., 2014; Rhodes et al., 2005) .
Conclusion
The present findings support the development of MOX as a novel pharmacotherapy for the treatment of AUD. We presented solid evidence showing that both acute and repeated administration of MOX can reduce ethanol intake across different models of self-administered drinking paradigms. Importantly, we observed no signs of overt toxicity and all animals remained alive at the end of the study. Of note, the safety and initial efficacy of coadministration of a single 30-mg dose of ivermectin and intravenous alcohol infusion in alcoholic patients was recently tested. In this study, ivermectin (30 mg) was found to be safe and well tolerated where the number and severity of reported adverse effects were low and did not differ from the placebo session (Roche et al., 2016) . Although ivermectin did not differ from placebo in regards to reducing alcohol cue-induced craving or basal alcohol craving, the study represented an important first step in developing this class of molecules as pharmacotherapies for AUD. In that MOX is currently being developed for use in humans as an alternative for ivermectin as an anti-parasitic coupled with the better pharmacokinetics and margin of safety (as compared to ivermectin) once fully approved for human use MOX should have the potential to be repurposed and rapidly advanced to the clinic for the treatment and/or prevention of AUD.
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